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osting by EAbstract Background: Thrombomodulin (TM) is a surface glycoprotein and expressed in many
cancers. The aim of the present study was to detect the expression levels of TM in plasma and urine
of bladder cancer patients and to compare these levels to the clinicopathological data of the patients
as well as the ploidy status of their exfoliated urinary cells. We studied the levels of TM in plasma
and urine samples of 57 bladder cancer patients and 10 controls using the (ELISA) assay and com-
pared the results to the ploidy status of the cells taken from the patents urine samples as well as their
clinicopathological proﬁle.
Results: Urinary TM was signiﬁcantly down regulated while plasma TM was signiﬁcantly up
regulated in bladder cancer patients. Plasma TM was signiﬁcantly higher in SCC than TCC
patients. The sensitivity and speciﬁcity of urinary TM were 90% and 86%, respectively. While
the sensitivity and speciﬁcity of plasma TM were 76% and 80%, respectively.ollege of Applied Medical
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68 L.A. Refaat et al.Conclusion: Urinary TM is signiﬁcantly down regulated, while plasma TM is signiﬁcantly up
regulated in bladder cancer as compared to the control group. Urinary TM has superior sensitivity
and speciﬁcity over plasma TM. Urinary TM could be used as a predictive marker in bladder
cancer. Further studies are needed to detect the prognosis signiﬁcance of thrombomodulin in schis-
tosomiasis associated bladder cancer.
ª 2012 Academy of Scientific Research & Technology. Production and hosting by Elsevier B.V.
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Thrombomodulin is a thrombin receptor expressed on the
endothelium which acts as a cofactor for thrombin-catalyzed
activation of protein C [6,8]. The presence of thrombomodulin
was demonstrated throughout the vascular and lymphatic
endothelium, and syncytio-trophoblast [16]. Circulating TM
reﬂects proteolysis of endothelial membrane TM that is pro-
duced either as a result of the turnover of TM or as a result
of endothelial damage in areas of endothelial injury or inﬂam-
mation [4,6,9]. Recent studies revealed that thrombomodulin is
expressed in varying amounts by different additional cell types
including platelets [21] and monocytes [22]. Since these cells
come in contact with the blood, thrombomodulin on these cells
may regulate blood coagulation on the cell surface. Thrombo-
modulin is also reported to be expressed in the squamous epi-
thelium and carcinoma, suggesting that thrombomodulin may
play some role in cell–cell interaction [8]. Thrombomodulin
has been reported to be present in plasma P-TM as well as
in urine U-TM [21], in various molecular forms and with dif-
ferent electrophoretic motilities [22]. P-TM is probably re-
leased from endothelial cell membranes by proteolytic
cleavage and its level is increased in disease possibly involving
endothelial cell injury [8]. The level of circulating P-TM may
be useful as a critical marker of vascular endothelial damage,
disease recurrence and angiogenesis in certain malignancies
[9]. The electrophoretic mobility of U-TM was found to be
similar to that of P-TM and lack 29 amino acid of the c-termi-
nal sequence of cellular thrombomodulin [12]. According to
studies conducted in the National Cancer Institute of Egypt:
bladder cancer continues to be the most frequent cancer today
in Egyptian men and 32% of all malignant tumor registered in
the NCI. It tends to occur at unpredictive course and limited
tendency to lymphatic and blood stream spread [1,2,3].
Tumor metastasis is a complex series of multi-step process.
One process is the detachment of cancer cells into blood circu-
lation and another is the adhesion of such cells to endothelial
cells [13]. Several investigators have previously reported on the
relationship between coagulation activity and tumor metasta-
sis. Thrombomodulin was demonstrated recently to be ex-
pressed on the urinary bladder epithelium. Thrombomodulin
is known to inhibit ﬁbrin formation and platelet activation
that stimulates tumor cell bindings to endothelial cells. There-
fore it is critical to the pathogenesis of tumor growth and
metastasis formation [15,18]. In this study we evaluated the
expression levels of both urinary and plasma soluble thrombo-
modulin in bladder cancer patients and its relation to the cli-
nico-pathological data as well as the DNA ploidy status to
these patients.2. Patients and methods
This study included a total of 58 cases with diagnosed bladder
cancer attending to the National Cancer Institute – Egypt and
10 aged matched normal controls.
Inclusion criteria: only new cases with clinically diagnosed
bladder cancer were involved in the study. Selection of the pa-
tients have been done depending on the results of endoscopy.
After approval of the ethical committee of the National
Cancer Institute, Cairo University, samples were collected
from the patients before being subjected to any type of ther-
apy. For those who had radical cyctectomy as a primary treat-
ment modality, diagnosis of bladder cancer was conﬁrmed by
histo-pathological examination of the removed tumor tissues.
Thrombomodulin in both urine and plasma levels were deter-
mined using the enzyme linked immunosorbent assay (ELI-
SA). The ploidy status analysis was done on exfoliated cells
separated from 39 urinary samples using the ﬂow cytometry.2.1. Methods
Blood samples were collected from patients on 3.2% trisodium
citrate solution as an anti coagulant. The samples were centri-
fuged at 3000 rpm for 20 min. Plasma was separated and
stored in 80 C. Fifty milli liters of voided morning urine
samples were collected from patients into 50 ml sterile Falcon
tubes before therapy and transferred to the laboratory. Urine
samples were centrifuged at 1200 rpm for 20 min. The superna-
tant was separated in a separate sterile tube and kept frozen at
80 C, while the cell pellets of the urine samples were washed
with PBS (pH 7.2), centrifuged again. The pellets were re sus-
pended in PBS and the cells were counted where the total vol-
ume was diluted to 1 million cells/ml and transferred to the
ﬂow cytometry laboratory. The DNA ploidy status of the cells
was detected using FACS Calibur BECTON DICKNSON
ﬂow cytometry model. The FACS caliber is adjusted to with-
draw 10,000 cells from each sample. Samples were run and
proper gating of desired population was done to exclude any
debris. The thrombomodulin in plasma and urinary samples
was measured by using a two-site enzyme-linked immunosor-
bent assay (ELISA) purchased from Diagnostica Stago [21].3. Results
The DNA ploidy status was studied on a total of 39 samples.
Twenty-ﬁve cases (64.1%) were diploid and 14 (35.9%) cases
were aneuploid (Table 1).
Table 2 The mean values for TM in patients and control
groups.
TM (ng/ml) Mean value in
patient group
Mean value in
control group
P value
Plasma 59.2 30.3 0.006**
Urine 360.9 868.3 0.00001**
** P value is highly signiﬁcant.
Table 1 The numbers of diploid and aneuploid cells in the
exfoliated urinary cells in 39 bladder cancer cases.
Ploidy Number %
Diploid 25 64.1
Aneuploid 14 35.9
Total 39 100
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higher signiﬁcant mean value as compared to the mean value
of P-TM in normal healthy control group (59.2 vs. 30.3)
p= 0.006** (Table 2).
P-TM in bladder cancer patients were correlated to the cli-
nico-pathological ﬁndings: (Table 3). There was no statistically
signiﬁcant correlation between the level of TM-P and any of the
clinic-pathological parameters including age, sex, bilharzial
infection, histopathological grade, clinical stage lymph node
involvement. By studying the correlation between TM-P and
tumor size we found that there was a positive correlationTable 3 The correlation between TM levels and the clinicopatholo
Characteristics of patients Number % P-TM mea
Sex
Male 46 79.3 57.3 ± 29
Female 12 20.7 66.5 ± 57.
Age
P60 25 43.1 47.9 ± 21.
660 33 56.9 67.7 ± 42.
Pathologic subtype
SCC 23 76 ± 46.9
TCC 33 56.8 48 ± 22.2
Pathologic grade
I + II 36 62 62.5 ± 38.
III 22 38 53.7 ± 32.
Staging
P1, P2, P3a 31 63.2 54.3 ± 25.
P3b, P4 18 36.8 60.6 ± 36.
L.N involvement
Negative 27 69.2 56.8 ± 26.
Positive 12 30.8 44.3 ± 22.
Bilharzial infestation
Negative 23 39.6 56.5 ± 44
Positive 35 60.4 60.9 ± 31
Tumor size
5 cm 15 39.4 43.8 ± 21.
P5 cm 23 60.6 62.4 ± 33
* P value is signiﬁcant.between the level of P-TM and the tumor size but the
correlation did not reach the level of signiﬁcance (P= 0.063).
However, P-TM was signiﬁcantly higher in SCC patient as
compare to TCC patients (76 ± 46.9 vs. 48 ± 22.2) P= 0.019.
By studying the DNA Ploidy status in exfoliated urinary
cells of the 39 bladder cancer cases, we found that P-TM
showed higher mean values in aneuploid as compared to dip-
loid however the difference failed to reach the level of signiﬁ-
cant values p= 0.180 (Table 4).
We used the ROCK curve to study the sensitivity and spec-
iﬁcity of TM-P (Fig. 1). Sensitivity was 76% while the speciﬁc-
ity was 80%.
U-TM in cancer bladder patient showed statistically signif-
icant reduction of the mean value as compared to the normal
control U-TM (360.9 vs. 868.3) p= 0.00001** (Table 2).
We did not ﬁnd any signiﬁcant correlation between the lev-
els of U-TM in bladder cancer patients and any of the clinico-
pathological criteria including age, sex, tumor type, tumor
grade, clinical stage, lymph node metastasis, bilharzial infec-
tion and tumor size: (Table 3). There was no signiﬁcant corre-
lation between the results of the ploidy status and the levels of
TM-Whereas the levels of U-TM were the same in both groups
(P= 0.9) (Table 4). The ROCK curve analysis showed that
the sensitivity and speciﬁcity of U-TM were 90% and 86%,
respectively (Fig. 2).4. Discussion
We reported the presence of soluble TM in plasma and
urine of normal subjects as well as in bladder cancer. Ourgical data of the patients.
n values P values U-TM mean values P values
0.3 58.9 ± 26.4 0.177
8 72 ± 51.6
9 0.06 43.8 ± 21.4 0.11
7 62.4 ± 33
0.019* 356.1 ± 204.7 0.83
369.7 ± 254.3
7 0.3 364.4 ± 240.9 0.89
3 355.3 ± 217.7
8 0.56 308.2 ± 210 0.41
6 407.6 ± 223.3
6 0.187 354.2 ± 208.6 0.27
9 484.6 ± 268.8
0.72 74.2 ± 49.7 0.065
56.3 ± 24.3
4 0.063 343.6 ± 177.5 0.68
371.1 ± 255.4
Table 4 The correlation between TM-levels and the DNA ploidy status of the exfoliated urinary cells.
Ploidy status Number P-TM Mean score P value U-TM Mean score P value
Diploid 25 58.9 ± 26.4 0.180 398.8 ± 235.4 0.9
Aneuploid 14 72 ± 51.6 398.9 ± 198.9
Total 39
Figure 1 Shows the sensitivity and speciﬁcity of P-TM.
Figure 2 Shows the sensitivity and speciﬁcity of U-TM
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physiological signiﬁcance were obscure [16]. In our study the
mean level of U-TM was 28 folds higher than P-TM in the nor-
mal control group. The difference in the level of TM in plasma
and urine in normal subjects could be attributed to their differ-
ent origin [11,12].
In the present study the soluble TM in plasma tends to sig-
niﬁcantly increase in bladder cancer as compared to healthy
normal control. It is known that cancer patients may haveincreased amounts of proteolytic enzymes in plasma, which
could explain increased levels of circulating TM fragments
[16]. P-TM levels higher than normal were noticed in all termi-
nal phase cancer cases [14]. This increase may be due to in-
creased endothelial cell damage upon chemical damage and
by activated polymorph nuclear white cells. Additional mech-
anisms for endothelial injury in cancer are the marked interac-
tion of cytokine-activation lymphocyte with cytokine-
activation endothelial cells causing endothelial cell damage
leading to increase TM levels and T-helper 2 cell pattern sup-
porting a humoral autoimmune process. However, this does
not exclude the possibility that some tumor cells may secrete
TM in vivo [5,13]. It is probably inﬂuenced by several or all
of these mechanisms.
According to this study soluble TM in plasma was statisti-
cally higher in SCC as compared to TCC. In conﬂict with our
results, previous trials using immunohistochemical staining of
TM in different cancer types to distinguish TCC from SCC
proved that it was of no practical value. On 2011 Tsuta K
and colleagues examined a panel of 10 antibodies including
TM to distinguish SCC from AC of the lung. Although the
sensitivity and speciﬁcity of TM was 79.3% and 79.9%, respec-
tively, he found other marker more sensitive and more speciﬁc
than TM. He concluded that CK5/6 is the best marker for dif-
ferentiating SCC and AC and the combination of CK5/6 and
TIF-1 is the most recommended combination of immunohisto-
chemical markers. [23]. However we found a statistically non
signiﬁcant difference between the level of P-TM and tumor
grade, clinical stage, lymph node status as well as DNA ploidy
status. On the other hand there was a borderline signiﬁcant po-
sitive correlation between the level of P-TM and tumor size
(P= 0.063).
It was suggested that the increased cleavage of endothelial
TM is unfavorable for cancer patients and contribute to the
imbalance in homeostasis observed in these patients; this could
explain the tendency to higher P-TM in our study in bladder
cancer with indications of aggressiveness [17,18]. P-TM level
showed great variation between different cancer types: as in
lung cancer, pancreases, colorectal, gastrointestinal but failed
to reach statistical signiﬁcance except in progression of malig-
nant disease and terminal metastasis [10,14,16]. P-TM in can-
cer lung was extensively studied: on 1999 Yelmaz et al.
reported that the concentration of soluble TM in plasma of
lung cancer patients was of non-signiﬁcant value as compared
to control. Zekanowaska on 2001 noted that no difference be-
tween patients at different stages of lung cancer and considered
TM as an unacceptable tumor marker in lung cancer. [13,16].
On the contrary, soluble TM tends to signiﬁcantly decrease
in urine of bladder cancer as compared to healthy normal
controls. Investigators noted that the epithelium of the urinary
bladder normally expresses thrombomodulin at both mRNA
and protein levels [8]. Other investigators ascertained
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der by immunohistochemical staining which is localized in the
membranes of the transitional epithelium and the cytoplasmic
region of umbrella cells. Based on these results it was con-
cluded that TM in urine might be partially derived from uri-
nary bladder [7]. However some investigators assumed that
U-TM is probably derived from plasma [20].
Recently, it was demonstrated that TM is expressed on the
surface of several tumor cells using immunohistochemistry and
its degree of expression negatively correlated with malignancy
in cancer [18]. This was conﬁrmed in our study which shows a
signiﬁcant reduction in the level of soluble U-TM in bladder
cancer as compared to normal controls. They explained the de-
crease of the TM associated with cancer as it probably involves
the presence of a factor secreted by the tumor cells, responsible
for a decrease in TM synthesis in endothelial cells, as is
in vitro: inﬂammatory cytokines (IL-1, TNF alpha) have been
shown to reduce TM synthesis in cultured endothelial cells
[19]. The decrease in TM level may also be related to the meth-
ylation of the TM promoter region, Nocchi and colleagues on
2011 found that the methylation of TM promoter is responsi-
ble for silencing of TM expression in malignant mesothelioma
tissue. [24]. Hossaka et al. on 2000 reported that soluble TM
isolated from human urine affects the invasion and metastasis,
while Kaido et al. 1999 used U-TM to ameliorate ﬁbrin depo-
sition, hepato-cellular necrosis and improve the survival rate of
control rats [10,11].
By analyzing the sensitivity and speciﬁcity of both urinary
and plasma TM, we found that U-TM was more sensitive
and more speciﬁc than P-TM. This result may suggest a possi-
ble urinary bladder cancer cell origin for U-TM and also sug-
gest a possible role for U-TM as a predictive marker in bladder
cancer.
5. Conclusion
The results of the present study may show the following: 1 –
U-TM is signiﬁcantly down regulated in bladder cancer as
compared to normal control group. 2 – P-TM is signiﬁcantly
up regulated in bladder cancer in relation to the control group.
3 – U-TM has superior sensitivity and speciﬁcity over P-TM. 4
– A possible role of U-TM in the prediction of urinary bladder
cancer 5 – Other Studies are clearly needed to test the prognos-
tic role of U-TM in bladder cancer.
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